Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

MedWellAI (MWAI) Capital Expenditures (2017 - 2024)

MedWellAI has reported Capital Expenditures over the past 8 years, most recently at $2242.0 for Q4 2024.

  • Quarterly Capital Expenditures rose 28.85% to $2242.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2242.0 through Jun 2025, changed N/A year-over-year, with the annual reading at $2242.0 for FY2025, N/A changed from the prior year.
  • Capital Expenditures was $2242.0 for Q4 2024 at MedWellAI, up from -$1740.0 in the prior quarter.
  • Over five years, Capital Expenditures peaked at $2.4 million in Q2 2023 and troughed at -$1740.0 in Q2 2024.
  • The 5-year median for Capital Expenditures is $33396.5 (2022), against an average of $480019.8.
  • Year-over-year, Capital Expenditures surged 10916.33% in 2021 and then plummeted 100.07% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $171605.0 in 2020, then plummeted by 96.05% to $6782.0 in 2021, then surged by 563.52% to $45000.0 in 2022, then plummeted by 96.13% to $1740.0 in 2023, then increased by 28.85% to $2242.0 in 2024.
  • Per Business Quant, the three most recent readings for MWAI's Capital Expenditures are $2242.0 (Q4 2024), -$1740.0 (Q2 2024), and $1740.0 (Q4 2023).